Clinical Trials Logo

Inadequate Glycaemic Control clinical trials

View clinical trials related to Inadequate Glycaemic Control.

Filter by:
  • None
  • Page 1

NCT ID: NCT02681094 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Start date: February 26, 2016
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.

NCT ID: NCT02471404 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Start date: September 21, 2015
Phase: Phase 4
Study type: Interventional

This study is being carried out to see if dapagliflozin and dapagliflozin plus saxagliptin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glimepiride (sulphonylurea) as an addition to metformin treatment.

NCT ID: NCT01392677 Completed - Clinical trials for Type 2 Diabetes Mellitus

Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Start date: October 2011
Phase: Phase 3
Study type: Interventional

This study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.

NCT ID: NCT01042977 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Start date: March 2010
Phase: Phase 3
Study type: Interventional

This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease

NCT ID: NCT01031680 Completed - Hypertension Clinical Trials

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Start date: February 2010
Phase: Phase 3
Study type: Interventional

This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes, cardiovascular disease and hypertension.